Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator

Journal of Clinical Hypertension

Volumn 11, Issue 10, 2009, Pages 555-563

  Young, Kate C ^a,b   Teeters, J C ^a   Benesch, Curtis G ^a   Bisognano, John D ^a   Illig, Karl A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CAROTID SINUS MASSAGE; COST EFFECTIVENESS ANALYSIS; DEVICE REMOVAL; DRUG TREATMENT FAILURE; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HIDDEN MARKOV MODEL; HYPERTENSION; KIDNEY FAILURE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCANDINAVIA; SENSITIVITY ANALYSIS; STROKE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAROTID BODY; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; FUMARATES; HUMANS; HYPERTENSION; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 70350261493     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00163.x     Document Type: Article

References (57)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
2. de Leeuw P, Bisognano J, Cody R. Chronic Treatment of Resistant Hypertension with an Implantable Device: Preliminary Results of European and United States Trials of Rheos™ Baroreflex Activation, Presented at Session 2406 of the 56th Annual Scientific Sessions of the American College of Cardiology in New Orleans, 2007.
3. Scheffers I, Schmidli J, Kroon AA, et al. Susteined Blood Pressure Reduction by Baroreflex Hypertension Therapy with a Chronically Implanted System: 2-Year Data from the Rheos(r) DEBuT-HT Study in Patients with Resistant Hyptertension. J Hypertens. 2008;26(suppl1): S19.
4. Bisognano JD, de Leeuw PW, Bach DS, et al. Improved Cardiac Structure and Function in Early-Stage Heart Failure with Chronic Treatment Using an Implantable Device: Results from European and United States Trials of the Rheos(r) System. J Card Fail. 2008;14(No.6S suppl): S48.
5. Tekturna(r). Rev: Dec 2007, T2007-111/T2007-112 ed. East Hanover, NJ: Novartis; 2007.
6. Johannesson M, Jonsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics. 1992;1:250-264.
7. Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: A Markov decision analysis. J Hypertens. 2003;21:1753-1759.
8. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:1197-1204.
9. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293-298.
10. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: A risk profile from the Framingham Study. Stroke. 1991;22:312-318.
11. Hsu CY, McCulloch CE, Darbinian J, et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165:923-928.
12. Brown RD Jr, Petty GW, O'Fallon WM, et al. Incidence of transient ischemic attack in Rochester, Minnesota, 1985-1989. Stroke. 1998;29:2109-2113.
13. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics -2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
14. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366:895-906.
15. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907-913.
16. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
17. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26:2300-2304.
18. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81:1110-1115.
19. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation. 2000;101:366-371.
20. Kilaru S, Korn P, Kasirajan K, et al. Is carotid angioplasty and stenting more cost effective than carotid endarterectomy? J Vasc Surg. 2003;37:331-339.
21. Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007;115:2398-2409.
22. Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117:1261-1268.
23. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med. 2006;166:112-118.
24. Liao L, Anstrom KJ, Gottdiener JS, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J. 2007;153:245-252.
25. Trogdon JG, Finkelstein EA, Nwaise IA, et al. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007;8:234-242.
26. Kuntz KM, Kent KC. Is carotid endarterectomy cost-effective? An analysis of symptomatic and asymptomatic patients. Circulation. 1996;94(9suppl):II194-II198.
27. Cronenwett JL, Birkmeyer JD, Nackman GB, et al. Cost-effectiveness of carotid endarterectomy in asymptomatic patients. J Vasc Surg. 1997;25:298-309.
28. Post PN, Kievit J, van Baalen JM, et al. Routine duplex surveillance does not improve the outcome after carotid endarterectomy: A decision and cost utility analysis. Stroke. 2002;33:749-755.
29. Lee WC, Joshi AV, Wang Q, et al. Morbidity and mortality among elderly Americans with different stroke subtypes. Adv Ther. 2007;24:258-268.
30. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706.
31. Holloway RG, Witter DM Jr, Lawton KB, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.
32. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2005. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed November 25, 2008.
33. Stein JD, Brown GC, Brown MM, et al. The quality of life of patients with hypertension. J Clin Hypertens (Greenwich). 2002;4:181-188.
34. Hornberger JC, Best JH, Garrison LP Jr. Cost-effectiveness of repeat medical procedures: Kidney transplantation as an example. Med Decis Making. 1997;17:363-372.
35. Kroeker A, Clark WF, Heidenheim AP, et al. An operating cost comparison between conventional and home quotidian hemodialysis. Am J Kidney Dis. 2003;42(1suppl):49-55.
36. Austin J, Williams WR, Ross L, et al. Five-year follow-up findings from a randomized controlled trial of cardiac rehabilitation for heart failure. Eur J Cardiovasc Prev Rehabil. 2008;15:162-167.
37. Eurich DT, Johnson JA, Reid KJ, et al. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes. 2006;4:89.
38. Masoudi FA, Rumsfeld JS, Havranek EP, et al. Age, functional capacity, and health-related quality of life in patients with heart failure. J Card Fail. 2004;10:368-373.
39. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005;7:243-251.
40. Haacke C, Althaus A, Spottke A, et al. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke. 2006;37:193-198.
41. Kim DH, Haney CL, Van GG. Utility of outcome measures after treatment for intracranial aneurysms: A prospective trial involving 520 patients. Stroke. 2005;36:792-796.
42. Samsa GP, Matchar DB, Goldstein L, et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J. 1998;136(4Pt1):703-713.
43. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: A systematic review of the literature. Stroke. 2001;32:1425-1429.
44. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
45. Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke. 1994;25:1721-1725.
46. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-165.
47. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1851-1858.
48. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation. 1995;92:2811-2818.
49. Gold MR, Siegel JE, Russell B, et al, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
50. HCUP Nationwide inpatient sample (NIS). Healthcare cost utilization project (HCUP). http://www.hcup-usahrq.gov/nisoverview.jsp 2006; (2006). Accessed June 10, 2009.
51. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-1480.
52. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: A cost-effectiveness analysis. Neurology. 2001;57:663-671.
53. Clegg AJ, Scott DA, Loveman E, et al. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: A systematic review and economic evaluation. Int J Technol Assess Health Care. 2007;23:261-268.
54. Anis AH, Sun H, Singh S, et al. A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. Pharmacoeconomics. 2006;24:387-400.
55. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743.
56. El-Saed A, Kuller LH, Newman AB, et al. Geographic variations in stroke incidence and mortality among older populations in four US communities. Stroke. 2006;37:1975-1979.
57. McGuire AJ, Raikou M, Whittle I, et al. Long-term mortality, morbidity and hospital care following intracerebral hemorrhage: An 11-year cohort study. Cerebrovasc Dis. 2007;23: 221-228.